Login / Signup

Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial.

Marta RicartErika BonacinaPablo Garcia-ManauMonica LópezSara CaamiñaÀngels VivesEva Lopez-QuesadaAnna MarotoLaura de MingoElena PintadoRoser Ferrer-CostaLourdes MartínAlicia Rodriguez-ZuritaEsperanza GarciaMar PallarolsLaia PratcoronaMireia TeixidorCarmen Orizales-LagoVanesa OcañaEsther Del BarcoElena CarrerasAnna SuyManel Mendoza
Published in: Acta obstetricia et gynecologica Scandinavica (2024)
Discontinuation of aspirin treatment at 24-28 weeks in women with PlGF levels ≥100 pg/mL was non-inferior to continuing until 36 weeks for preventing preterm PE. However, these findings should be interpreted with caution, as they originate from a subanalysis of the StopPRE trial.
Keyphrases